Australia, Feb. 10 -- Pharvaris Gmbh, owns the trademark (2595236) for 'HAEBRII' till Sept. 15, 2035.
Status: protected:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment and prevention of rare and orphan diseases and disorders; pharmaceutical preparations for the treatment and prevention of hematological diseases and disorders; pharmaceutical preparations for the treatment and prevention of inflammatory diseases and disorders; pharmaceutical preparations for the treatment and prevention of genetic diseases and disorders; pharmaceutical preparations for the treatment and prevention of hereditary angioedema (HAE); pharmaceutical preparations for the treatment and prevention of bradykinin mediated angioedema; pharmaceutical preparations for the treatment and prevention of acquired angioedema.] and 44 [Providing medical information to healthcare providers and patients relating to hematological, inflammatory, genetic, and rare diseases and disorders; providing medical information, namely, providing healthcare providers and patients with information, assistance and support regarding clinical aspects, disease management resources, and access to pharmaceuticals for the treatment and prevention of hereditary angioedema.]
Type of Mark: Word
Date of Acceptance: Oct. 27, 2025
Registration Advertised: Feb. 9
For further details contact Makiko Coffland Christensen O'Connor Johnson Kindness.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2595236.
Disclaimer: Curated by HT Syndication.
